168 related articles for article (PubMed ID: 19259668)
1. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
Britten CM; Janetzki S; Ben-Porat L; Clay TM; Kalos M; Maecker H; Odunsi K; Pride M; Old L; Hoos A; Romero P;
Cancer Immunol Immunother; 2009 Oct; 58(10):1701-13. PubMed ID: 19259668
[TBL] [Abstract][Full Text] [Related]
2. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
Janetzki S; Panageas KS; Ben-Porat L; Boyer J; Britten CM; Clay TM; Kalos M; Maecker HT; Romero P; Yuan J; Kast WM; Hoos A;
Cancer Immunol Immunother; 2008 Mar; 57(3):303-15. PubMed ID: 17721781
[TBL] [Abstract][Full Text] [Related]
3. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
Attig S; Price L; Janetzki S; Kalos M; Pride M; McNeil L; Clay T; Yuan J; Odunsi K; Hoos A; Romero P; Britten CM;
J Transl Med; 2011 Jul; 9():108. PubMed ID: 21745365
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial detection of autoreactive CD8
James EA; Abreu JRF; McGinty JW; Odegard JM; Fillié YE; Hocter CN; Culina S; Ladell K; Price DA; Alkanani A; Rihanek M; Fitzgerald-Miller L; Skowera A; Speake C; Gottlieb P; Davidson HW; Wong FS; Roep B; Mallone R;
Diabetologia; 2018 Mar; 61(3):658-670. PubMed ID: 29196783
[TBL] [Abstract][Full Text] [Related]
5. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
6. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).
McNeil LK; Price L; Britten CM; Jaimes M; Maecker H; Odunsi K; Matsuzaki J; Staats JS; Thorpe J; Yuan J; Janetzki S
Cytometry A; 2013 Aug; 83(8):728-38. PubMed ID: 23788464
[TBL] [Abstract][Full Text] [Related]
7. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.
Gouttefangeas C; Chan C; Attig S; Køllgaard TT; Rammensee HG; Stevanović S; Wernet D; thor Straten P; Welters MJ; Ottensmeier C; van der Burg SH; Britten CM
Cancer Immunol Immunother; 2015 May; 64(5):585-98. PubMed ID: 25854580
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
10. Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI).
Price LS; Adamow M; Attig S; Fecci P; Norberg P; Reap E; Janetzki S; McNeil LK
Cytometry A; 2021 Jan; 99(1):107-116. PubMed ID: 33090656
[TBL] [Abstract][Full Text] [Related]
11. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
12. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
[TBL] [Abstract][Full Text] [Related]
13. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.
Harada M; Gohara R; Matsueda S; Muto A; Oda T; Iwamoto Y; Itoh K
J Immunol; 2004 Feb; 172(4):2659-67. PubMed ID: 14764741
[TBL] [Abstract][Full Text] [Related]
14. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
15. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
[TBL] [Abstract][Full Text] [Related]
16. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
17. Harmonization of the intracellular cytokine staining assay.
Welters MJ; Gouttefangeas C; Ramwadhdoebe TH; Letsch A; Ottensmeier CH; Britten CM; van der Burg SH
Cancer Immunol Immunother; 2012 Jul; 61(7):967-78. PubMed ID: 22714399
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine.
Matsueda S; Shichijo S; Nagata S; Seki C; Yamada A; Noguchi M; Itoh K
Cancer Sci; 2015 Nov; 106(11):1493-8. PubMed ID: 26331453
[TBL] [Abstract][Full Text] [Related]
19. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
20. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
